Finance

Lists
Q2 2026 earnings • released • EPS miss -6.59% • Revenue miss -5.97%
See results
ZYME:NASDAQ
Zymeworks Inc
$23.54
+1.77%
(+0.41) 1D
$23.14
-1.70% (-0.40)
After hours
Closed: Aug 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZYME...
Open
$24.10
High
$24.76
Low
$23.18
Mkt. cap
1.69B
Avg. vol.
521.91K
Volume
578.11K
52-wk high
$29.75
52-wk low
$11.51
EPS
-$1.37
Beta
1.15
Shares outstanding
73.02M
No. of employees
243
Open
$24.10
High
$24.76
Low
$23.18
Mkt. cap
1.69B
Avg. vol.
521.91K
Volume
578.11K
52-wk high
$29.75
52-wk low
$11.51
EPS
-$1.37
Beta
1.15
Shares outstanding
73.02M
No. of employees
243
News stories
From sources across the web
Profile
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
About Zymeworks Inc
CEOKenneth Galbraith
Employees243
Founded2003
HeadquartersMiddletown, Delaware, United States
SectorBiotechnology
Websitezymeworks.com
Analyst ratings
Based on 9 analysts giving stock ratings to ZYME in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ZYME in the last 3 months.
Highest
Current $23.54
$51.00 (+116.65%)
Average
$39.89 (+69.46%)
Lowest
$32.00 (+35.94%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$46.00
+95.4%
08/07/2026
Gregory Renza
Truist Financial
Buy
Maintained
$32.00
+35.9%
08/07/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$34.00
+44.4%
08/06/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
$40.00
+69.9%
08/07/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$51.00
+116.7%
08/05/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
$40.00
+69.9%
07/30/2026
Unknown Analyst
Jefferies
Buy
Maintained
$43.00
+82.7%
06/30/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$37.00
+57.2%
06/30/2026
David Martin PhD
Bloom Burton
Buy
Maintained
$36.00
+52.9%
06/29/2026
Asthika Goonewardene
Truist Financial
Buy
Initiated
$28.00
+18.9%
06/09/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
05/08/2026
Mayank Mamtani
B. Riley Securities
Buy
Reiterated
$40.00
+69.9%
04/10/2026
Jonathan Miller
Evercore ISI
Buy
Reiterated
$48.00
+103.9%
03/09/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
-
-
03/03/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.62 / -$0.58
-6.59%miss
Revenue / Est. (USD)
4.59M / 4.88M
-5.97%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
27.61M
2.52M
2.41M
4.59M
Cost of goods sold
35.58M
31.24M
34.46M
-
Cost of revenue
35.58M
31.24M
34.46M
-
Research and development expenses
-
-
-
27.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.15M
15.43M
15.07M
19.34M
Operating expense
14.15M
15.43M
15.07M
46.77M
Total operating expenses
49.72M
46.67M
49.53M
46.77M
Operating income
-22.11M
-44.15M
-47.12M
-42.18M
Other non operating income
26.00K
-18.00K
120.00K
196.00K
EBT including unusual items
-18.27M
-41.48M
-46.35M
-45.29M
EBT excluding unusual items
-18.27M
-41.48M
-46.35M
-45.29M
Income tax expense
1.34M
-270.00K
-2.19M
-273.00K
Effective tax rate
-7.31%
0.65%
4.73%
0.60%
Other operating expenses
-
-
-
-
Net income
-19.60M
-41.21M
-44.16M
-45.02M
Net profit margin
-70.99%
-1,638.53%
-1,833.97%
-980.81%
Earnings per share
-0.26
-0.55
-0.59
-0.62
Interest and investment income
3.53M
2.98M
2.71M
3.29M
Interest expense
-
-
-2.07M
-6.60M
Net interest expenses
3.53M
2.98M
645.00K
-3.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.56M
-43.07M
-45.98M
-41.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps